Alnylam Pharmaceuticals: Bernstein cuts to market-perform from outperform; cuts target price to $199 from $376
ALNY•Bernstein cut its rating on Alnylam Pharmaceuticals to market-perform from outperform and lowered its target price to $199 from $376.
Related News
Five Star Bancorp: Stephens cuts target price to $49 from $50
FSBC•
Matador Resources raises 2026 midstream capital spending forecast to $170 million-$190 million
MTDR•
Sea CCO and GC Wang Yanjun reports sale of $120,719.94 in common shares
SE•
Melius Research cuts Marvell Technology target price to $300 from $445
MRVL•
Bank of Hawaii Corporation: Stephens cuts target price to $76 from $82
BOH•